前性痴呆. 前性痴呆. 如何应对其诊断复杂性?
Annibale Antonioni1,2, Emanuela Maria Raho2, Enrico Granieri2
1Doctoral Program in Translational Neurosciences and Neurotechnologies, University of Ferrara, Ferrara, FE, Italy.
Expert review of neurotherapeutics
|February 6, 2025
概括
早期诊断前性痴呆症 (FTD) 是一个挑战. 新的生物标志物,包括血液测试和功能神经成像,对于及时检测和治疗这种神经退行性疾病至关重要.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物标志物研究 生物标志物研究
背景情况:
- 前性痴呆症 (FTD) 是一种异质的神经退行性疾病.
- 早期诊断是困难的,因为模两可的症状和缺乏明显的早期神经影像模式,特别是在零星的情况下.
研究的目的:
- 审查疑似前性痴呆症 (FTD) 的既定和新兴诊断工具.
- 强调需要向使用生物标志物进行早期检测的范式转变.
主要方法:
- 在 MEDLINE,Scopus 和 Web of Science 的综合文献搜索.
- 对包括液体生物标志物,神经生理学测量和功能神经成像在内的诊断工具的审查.
主要成果:
- 基于血液的生物标志物可以识别早期的神经病理变化.
- 神经生理学和功能神经成像可以在症状出现前几十年检测FTD相关的变化.
- 认知行为特征和缩模式在晚期变得明显,有助于亚型分化.
结论:
- 转向早期诊断标记物,特别是液体生物标记物,对于及时干预至关重要.
- 功能神经成像和神经生理学测量对于检测临床前变化非常有价值.
- 监测主观投诉和行为的家庭技术可能有助于早期FTD诊断.
相关概念视频
Dementia
92
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
92
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Association Areas of the Cortex
4.9K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
4.9K


